The recent failure of active immunotherapies targeting beta-amyloid in Alzheimer’s disease has dampened some of the initial enthusiasm for this approach. Development of AN1792, an active beta-amyloid vaccine, was terminated following the development of meningoencephalitis in 6% of vaccinated subjects. This complication was attributed to use of full-length beta-amyloid1-42. Read More
Neurology
NeuroSound Radio at ACTRIMS/ECTRIMS 2014 – Part 2
November 19, 2014Toward a new standard in MS disease control
October 22, 2014REVIEWER: Dr. Mark S. Freedman, Director, Multiple Sclerosis Research Unit, The Ottawa Hospital, Ottawa, Canada
Redefining therapeutic efficacy
Conclusions
New data on novel and emerging therapies were the centrepiece of the 2014 joint meeting of the Americas and European Committee for Research and Treatment of Multiple Sclerosis (ACTRIMS/ECTRIMS), with results suggesting that clinical standards are being redefined for optimal disease control in relapsing-remitting multiple sclerosis (RRMS). Read More
Poor adherence to migraine prophylaxis
October 8, 2014Short-term adherence to migraine prophylaxis is poor, with about one-half of patients stopping their medication within a year, according to the results of a systematic review (Hepp et al. J Manag Care Pharm 2014;20:22-33). Read More
New data for daclizumab in MS
September 24, 2014Daclizumab is an IgG1 anti-CD25 monoclonal antibody that blocks IL-2-mediated lymphocyte activation. The drug (Zenapax) was originally used to prevent tissue rejection but was withdrawn by Roche in 2009 due to declining demand. Read More